Form 4: Verve Therapeutics Director and 10% Owner Granted Stock Options

Krishna Yeshwant, a Director and 10% Owner of Verve Therapeutics, Inc., was granted 42,200 stock options with an exercise price of $5.73 as part of the company's director compensation program.

Summary

• Krishna Yeshwant, a Director and 10% Owner of Verve Therapeutics, Inc. (VERV), acquired 42,200 stock options.
• The stock options have an exercise price of $5.73 per share.
• These options were granted on June 5, 2025, and are set to expire on June 4, 2035.
• The grant was made pursuant to the company's 2021 Stock Incentive Plan and is part of its director compensation program.
• The options vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on continued service as a director.

Sentiment

Score: 7

Explanation: The filing indicates a standard, positive action of aligning director incentives with shareholder value through equity compensation. It's a routine disclosure without negative implications.

Positives

• The grant of stock options aligns the interests of Director Krishna Yeshwant with those of shareholders, incentivizing long-term performance.
• The options were issued under the company's established 2021 Stock Incentive Plan, indicating a structured and transparent compensation framework.

Future Outlook

This filing primarily reports an insider transaction and does not contain forward-looking statements regarding the company's operational or financial performance, beyond the vesting schedule of the options.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning their interests with long-term company success. Verve Therapeutics operates in the gene editing space, where long-term strategic vision and executive incentives are crucial for innovation and development.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in high-growth sectors like biotechnology.
• While specific comparable companies or projects are not mentioned in this filing, the structure of the option grant (vesting over time, subject to service) is typical for incentivizing long-term commitment.
• Similar compensation structures are observed in companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) within the gene editing sector, where equity-based compensation forms a significant part of executive and director remuneration.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of a key director and 10% owner with long-term shareholder value creation.
• Employees: While this specific grant is for a director, it reflects the company's broader use of equity incentive plans, which can also benefit employees.

Next Steps

• The stock options will vest upon the earlier of the one-year anniversary of the grant date (June 5, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Key Dates

Keywords

Verve Therapeutics, VERV, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Krishna Yeshwant, Biotechnology, Gene Editing